SCHEMBL25539693

SCHEMBL25539693

CC1(C)c2cc3ccccc3cc2-c2cccc(-c3ccc(-c4nc(-c5ccccc5)cc(-c5ccccc5-c5cccc6ccccc56)n4)c4ccccc34)c21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.35
ALDH1A1 P00352 4/20 0.35
HPGD P15428 4/20 0.35
KDM4E B2RXH2 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
MAPK1 P28482 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
ATM Q13315 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 6/20 0.35
KMT2A Q03164 6/20 0.35
LMNA P02545 3/20 0.35
PIM1 P11309 1/20 0.34
ACACA Q13085 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25538398 0.97 MEN1 (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25539690 0.97 MEN1 (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25540326 0.97 MEN1 (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25538399 0.94 PIM1 (0.35) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25540477 0.94 PIM1 (0.35) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25540323 0.94 ACACA (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25539680 0.94 ACACA (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25539675 0.94 MEN1 (0.38) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25540320 0.94 MEN1 (0.38) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25540483 0.93 MEN1 (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-01 US disclosed
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE PIEZO1, LEF1, L1CAM MAPT 1595/4885ALDH1A1 254/4885HPGD 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.